logo
Twitter
Discord
Email
logo
Viking Therapeutics, Inc.

Viking Therapeutics, Inc.

NASDAQ•VKTX
CEO: Dr. Brian Lian Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2015-04-28
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Contact Information
9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, 92121, United States
858-704-4660
www.vikingtherapeutics.com
Market Cap
$3.83B
P/E (TTM)
-16.0
38.2
Dividend Yield
--
52W High
$43.15
52W Low
$18.92
52W Range
62%
Rank63Top 94.0%
1.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.81+268.18%
4-Quarter Trend

FCF

-$94.00M+328.03%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

R&D Spending Surge Nine-month R&D expenses hit $191.5M, marking a substantial 171.0% increase compared to $70.7M in 2024.
VK2735 Phase 3 Launch Initiated VANQUISH Phase 3 program for VK2735 subcutaneous dosing in June 2025 for obesity treatment.
Strong Cash Position Total cash and investments reached $714.6M as of September 30, 2025, funding operations through 2026.
Oral VK2735 Success Announced positive top-line results for oral VK2735 Phase 2 trial in August 2025, showing significant weight reduction.

Risk Factors

Accelerated Operating Losses Nine-month net loss widened to $(202.0M) in 2025 versus $(74.5M) in the prior comparable period.
High R&D Cost Burn Operating cash used increased to $(193.4M) for nine months due to advancing clinical studies costs.
Future Capital Requirements Expect continued material losses, necessitating raising additional equity or debt capital on uncertain terms.
Clinical Development Uncertainty Success of drug candidates is not guaranteed; regulatory approval may be delayed or denied across pipeline.

Outlook

Advance VK2735 Pipeline Continue advancing VK2735 subcutaneous Phase 3 and oral Phase 2 programs through clinical milestones.
Seek DACRA IND Filing Plan to file Investigational New Drug application for the DACRA obesity program in the fourth quarter of 2025.
Seek VK0214 Partnerships Intent to pursue partnering or licensing opportunities for the VK0214 X-ALD program following Phase 1b data.
Manage Lease Transition Executed amendment for new corporate headquarters lease, effective upon substitution date in early 2026.

Peer Comparison

Revenue (TTM)

ADMA Biologics, Inc.ADMA
$488.56M
+27.6%
Mirum Pharmaceuticals, Inc.MIRM
$471.79M
+53.7%
Ligand Pharmaceuticals IncorporatedLGND
$251.23M
+64.8%

Gross Margin (Latest Quarter)

NewAmsterdam Pharma Company N.V.NAMS
100.0%
+0.0pp
Crinetics Pharmaceuticals, Inc.CRNX
100.0%
+0.0pp
Soleno Therapeutics, Inc.SLNO
98.3%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
CRNX$5.74B-12.5-35.1%4.1%
KYMR$5.49B-20.6-33.4%7.6%
MIRM$4.71B-127.7-16.5%40.6%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 4, 2026
|
EPS:-$0.89
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Oct 23, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.81+268.2%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Jul 23, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.58+190.0%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: Apr 24, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.41+57.7%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 26, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.01-11.0%
    N/A

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Oct 23, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.22-4.3%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Jul 24, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.20+5.3%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: Apr 25, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.26+8.3%
    N/A

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 7, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.91-3.4%
    N/A